• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

CellRapeutics™ Anti-HBV CAR Cell Therapy Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Chronic hepatitis B virus (HBV) can cause decreased immunity and lead to the development of liver cancer. Based on CAR-T cell therapy, Creative Biolabs has designed a CAR-T cell that specifically recognizes Hepatitis B virus surface antigen (HBsAg) and provides in vitro/in vivo evaluation services.

Background

Existing treatments, such as antiviral medications (e.g., tenofovir, entecavir), can suppress HBV replication but do not typically eliminate the virus. These treatments often need to be taken lifelong and do not offer a cure. Anti-HBV CAR cell therapy is an advanced immunotherapy approach designed to treat chronic HBV infection. This therapy involves genetically modifying immune cells to specifically target and eliminate HBV-infected cells.

Fig.1 CAR T cells specific for HBV S protein.¹

Anti-HBV CAR Cell Therapy Development at Creative Biolabs

Creative Biolabs provides a one-stop solution for anti-HBV CAR cell therapy, a cutting-edge approach to the treatment of HBV infection. Here is a detailed description of each step:

As a leading supplier in the field of CAR, we also offer in vitro and in vivo evaluation services for HBV CAR:

• HBV CAR Cell In Vitro Assay Service
  Creative Biolabs offers in vitro testing of HBV CAR cells to evaluate the efficacy and function of CAR T cells specifically designed to target HBV-infected cells. These assays are essential for preclinical research and development, helping to ensure that engineered CAR T cells can effectively recognize and kill HBV-infected cells before they can be used in clinical trials or therapeutic applications.
  
  • HBV CAR Expression Test
  • Cytokine Release Test
  • In Vitro Cytotoxicity Test
  • Viability and Bio-distribution Analysis
  • Specificity Assay
• HBV CAR Cell In Vivo Assay Service
  Creative Biolabs offers in vivo detection of HBV CAR cells to assess the efficacy, safety, and function of CAR T cells specifically designed to target HBV-infected cells in animal models. These in vivo assays are essential for preclinical research and development, helping to ensure that engineered CAR T cells are effective in vivo before being used in human clinical trials.
  
  • HBV CAR-T Cell Therapy Animal Models
  • Efficacy Studies of HBV CAR-T
  • Toxicity Evaluation of HBV CAR-T
  • Viability and Bio-distribution Study of HBV CAR-T

Advantages of Anti-HBV CAR Cell Therapy

• Targeted Action: CAR T cells are designed to specifically recognize and kill HBV-infected cells, minimizing damage to healthy cells.
• Potential for a Cure: By eliminating HBV-infected cells, this therapy aims to achieve a functional cure, reducing or eliminating the need for lifelong antiviral medication.
• Overcoming Immune Tolerance: Chronic HBV infection can lead to immune tolerance, where the immune system does not effectively respond to the virus. CAR T cells can bypass this tolerance and mount a strong immune attack on the virus.
• Drug Resistance: CAR T-cell therapy offers an alternative to the problem of developing resistance to existing anti-HBV drugs.

Applications of Anti-HBV CAR Cell Therapy

Anti-HBV CAR cell therapy development has several important applications, primarily focused on treating chronic HBV infections and related complications. Here are some key applications:

Anti-HBV CAR cell therapy is being pursued because it offers a promising new approach to potentially cure chronic HBV infection, overcome the limitations of current treatments. If you are interested in this Anti-HBV CAR Cell Therapy Development Solutions, please feel free to contact us. Our technicians in the relevant field will be happy to assist you.

Reference

1. Seif, Michelle et al. "CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases." Frontiers in immunology. (2019) 10 2711.